anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: To characterize medical complexity and advanced interventions necessary to treat pediatric patients with chronic ear disease.
METHODS: A retrospective case review of children who received surgery for chronic otitis media, cholesteatoma, or tympanic membrane perforation at a tertiary children's hospital from 2020 to 2024 was performed. The frequency and type of medical complexities as well as distribution and success of advanced otologic interventions were recorded.
RESULTS: Operations were performed on 80 ears. Forty-five percent were in medically complex patients. Twenty-five percent had a syndrome, 13 % had American Society for Anesthesiologists Severity Class 3 or more, and 38 % attended multi-disciplinary programs. Advanced audiology testing protocols were utilized in 53 % of patients, and multiple children received complex sleep and airway operations. Advanced surgical techniques were required in 58 %. Post-operatively, an intact tympanic membrane was achieved in 95 % of operated ears (p < 0.01). Residual and recurrent cholesteatoma were each present in 5 % of cases, with mean follow-up of 11.6 months. Otorrhea reduced from 64 % of patients pre-operatively to 2 % post-operatively (p < 0.01), including cessation in all individuals who reported social/bullying issues related to ear drainage/odor. Unrestricted water exposure was achieved in 99 % of individuals (p < 0.01). Patients showed a mean improvement after surgery of 7.6 dB, as measured by the change in air-bone gap (p < 0.05).
CONCLUSIONS: Comprehensive treatment of otologic conditions included care that was holistic of all medical needs, integrated with other services, developmentally appropriate, encompassing of non-otologic procedures, technically advanced, effective, and functionally-focused. Surgical teams should endeavor together to provide this combination of services.
A spray-dried powdered organopolysiloxane composition consists of dry substantially spherical particles having a size from 5 to 1000 microns, each particle comprising a liquid organopolysiloxane coated with 15 to 95% by weight of the particle of a non-toxic coating material selected from acacia gum, guar gum, Ca-, Na- and NH4-caseinates, milk solids, polyvinyl alcohol, polyvinyl-pyrrolidone, methyl cellulose and carboxymethyl cellulose. If the coating material does not possess emulsifying properties, it may be mixed with a known emulsifying agent such as a sorbitan fatty acid ester.  In a typical Example 1A, methyl cellulose is dispersed in a liquid siloxane and the resulting dispersion is added to an aqueous solution of milk solids with subsequent homogenization to form an emulsion which is then spray-dried.  Uses.-For the treatment of gastrointestinal disorders when used in conjunction with an antacid (see Division A5).ALSO:A compressed table for the treatment of gastrointestinal disturbances, comprises pharmaceutically acceptable quantities of an antacid and a spray dried powdered organopolysiloxane composition consisting of dry spherical particles having a size from 5 to 1000 microns, each particle comprising a liquid organopolysiloxane coated with 15 to 95% (by wt. of the particle) of a non-toxic coating material selected from acacia and guargums, calcium-sodium-and ammonium caseinates, milk solids, polyvinylpyrrolidone, polyvinylalcohol, and methyl- and carboxymethyl-celluloses (see Div. C3).  Antacids specified are magnesium aluminium oxyhydroxide, aluminium hydroxide dried gel, aluminium phosphate, calcium carbonate, magnesium carbonate, magnesium trisilicate, magnesia, magnesium hydroxide and dihydroxyaluminium amino acetate.  In the Example, an antacid granulation is made by mixing a mixture of the antacid, glycine, mannitol and methylcellulose with a mixture of pyrrolidone (in alcohol) and saccharin, drying, screening and then mixing with flavour, lubricant and disintegrant.  A siloxane preparation is similarly made from the spray dried siloxane composition, mannitol, glycine, polypyrrolidone, saccharin, magnesium stearate, cornstarch and flavour.  The siloxane preparation may then be compressed to form a core in a tablet press with the antacid granulation, then either press coated around the siloxane core or pressed on to the initial siloxane slug to form a 2 or 3 layered tablet.
Per usual clinical care standards within the Center for Sleep Medicine at Mayo Clinic Arizona, all patients will receive instructions/education on positive airway pressure (PAP) use, multiple mask fittings, encouragement to use PAP every night, and staff is available in the event of problems. Control patients will also receive a wearable activity monitor to use during the study. The wearable sensor will be used to isolate the effect of SleepWell24 on PAP adherence from potential novelty effects due to receiving a generic health behavior change app.
Avapritinib tablets for oral administration. Avapritinib will be dosed daily for 28 day cycles.
Patients undergo IMRT or IMPT therapy QD on days 1-40 Monday-Friday for 28 or 35 fractions based on biomarker response along with concurrent cisplatin IV over 1-2 hours QW on Monday, Tuesday, or Wednesday or once every 3 weeks for 6 doses (or accepted alternate regimen when drug shortage applies per physician discretion). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo MBSS prior to RT and at 3 and 12 months post RT. Patients undergo CT, PET/CT, or MRI at baseline and 3 months and 1, 2 and 5 years post treatment. Patients undergo blood specimen collection for NavDx testing pre-RT, 4 weeks into RT, anticipated fraction 20, end of RT, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48, and 60 months as well as saliva sample collection at pre-op, end of RT, and any clinical recurrence.
<P>PROBLEM TO BE SOLVED: To use a nucleoside having a relatively low dosage range.  <P>SOLUTION: The administration of the nucleoside selectively modifying the reaction of Th1 and Th2, and other compound in the treatment of diseases decreases the dosage of an administered major medicine. In another aspect, an abnormality reflected on the increase of a reaction in one group of cytokines is treated by the administration of the nucleoside or other compound increasing the reaction of the other group of the cytokines. Further, in another aspect, by administering the nucleoside or other compound selectively decreasing the activity of the Th1 without significantly decreasing the activity of the Th2, patients can be treated preventively. Furthermore in another aspect, by a controlled release administration form, or the like, the nucleoside or other compound is administered to a patient by a dosage significantly decreasing a GTP (guanosine triphosphate) pool of the patient in an extent of selectively decreasing one of the reactions of the Th1 or Th2.  <P>COPYRIGHT: (C)2004,JPO
PURPOSE:A tape having improved solubility of drug and releasability, by starting polymerization in a state where total amount of a vinyl compound and part of (meth)acrylic ester are present, adding the rest to the copolymerization reaction, to form a pressure-sensitive adhesive layer having low residual ratio of vinyl compound. CONSTITUTION:A polymerization is started in a state where at least >=90wt% amide bond-containing polymerizable vinyl compound (e.g., vinyl pyrrolidone, alkylacrylamide, etc.) and 30-80wt% (meth)acrylic ester are present, each of the rest is gradually added to the copolymerization reaction, to give a pressure-sensitive adhesive agent wherein the vinyl compound is copolymerized with the ester in a molar ratio of 50:50-4:96. A solution of the pressure-sensitive agent is blended with an endermic absorption drug (e.g., vasodilator, anti-inflammatory agent, etc.), applied to a substrate by transfer method, etc., to give a pressure- sensitive adhesive tape or sheet for remedy. The tape or sheet has a small amount of residual vinyl compound, low irritation to the skin, and no deterioration of drug.
1. Use of radium-223 to produce a pharmaceutically active preparation to treat diseased bone and bone surfaces. 2. Use according to claim 1 wherein the preparation is used in a combination therapy with another therapeutically active component, such as but not limited to, chemotherapy including biphosphonates, surgery, external beam irradiation, low-LET radiation emitting bone seeking radiopharmaceuticals and hormonal treatment. 3. Use according to claims 1-2, wherein the preparation containing dissolved radium-223 salt is used for therapy and/or palliation related to non-malignant and malignant diseases affecting bones and/or soft tissues. 4. Use according to claim 3, wherein the malignant diseases are selected from the group consisting of prostate cancer, breast cancer, kidney and urinary cancer, primary bone cancer, lung cancer and multiple myeloma.
PURPOSE:To obtain the titled pack material capable of providing both effects on removal of dirt and cosmetic effects with high efficiency, by forming a pack agent composition containing a collagen hydrolyzate, water holding agent and liquefying agent having the cosmetic effects as principal ingredients in the form of layers. CONSTITUTION:A sheetlike pack material, obtained by forming a pack agent composition containing (A) a collagen hydrolyzate, e.g. gelatin, etc., (B) a water holding agent, e.g. glycerol, polyglycerol, sodium pyrrolidonecarboxylate, etc., and (C) a liquefying agent, e.g. urea, acetic acid, citric acid, calcium chloride, etc., as at least principal ingredients into the form of layers and preferably backing the layers with a backing sheet and capable of providing both cosmetic effects on impartment of moistness to the skin of the respective components and tackiness which can only be exhibited by combination thereof with high efficiency. The amounts of the above-mentioned ingredients are preferably 20-94pts.wt. ingredient (A), 5-70pts.wt. ingredient (B) and 1-30pts.wt. ingredient (C).
OBJECTIVES: Obesity and hypercholesterolemia are linked to unfavor clinical outcomes. Recent studies declared the paradox that high body mass index (BMI) and serum cholesterol were independently connected to better clinical outcome of immune checkpoint inhibitors (ICIs) monotherapy in non-small cell lung cancer (NSCLC). The aim of the study is to investigate the prognosis of BMI and serum cholesterol in ICIs-based therapy.
METHODS: This is a retrospective study of 95 NSCLC patients treated with ICIs-based therapy at the Department of Oncology and Lung Cancer Center of China-Japan Friendship Hospital. Treatment efficacy was assessed using durable clinical benefit (DCB) versus nondurable benefit (NDB), best response (active vs. nonactive), and progression-free survival (PFS). The prognostic value of BMI, LDL-C, and RC was determined by multivariate regression analyses, while controlling for confounding factors including age, gender, diabetes status, smoking history, and statin usage. BMI was considered a confounding factor in the analysis when examining the impact of lipoproteins.
RESULTS: In our study, we found that in the whole group, BMI ≥25 kg/m2 was linked to a higher risk of poor therapeutic response (OR = 5.92, 95% CI 1.99-19.51, p.val = 0.002) and shorter progression-free survival (HR = 3.00, 95% CI 1.59-5.68, p.val = 0.001). In addition, low levels of RC were associated with better therapeutic response (OR = 0.12, 95% CI 0.02-0.64, p.val = 0.019), while low levels of serum LDL-C were found to predict longer PFS (HR = 0.40, 95% CI 0.19-0.82, p.val = 0.012). These associations were consistent in advanced NSCLC patients receiving ICIs and chemotherapy.
CONCLUSIONS: Our study suggest that BMI ≥25 kg/m2 and elevated levels of apoB-containing lipoproteins, including LDL-C and RC, could potentially serve as useful prognostic markers for predicting poor treatment outcomes in advanced NSCLC patients treated with the combination of chemotherapy and ICIs.
FIELD: chemistry. ^ SUBSTANCE: viscoelastic composition which contains an effective amount of one or more polycationic quaternary ammonium compounds with a static or ordered structure for controlling viscoelastic properties of the composition. A viscoelastic liquid for processing drilled wells, which contains water and at least one polycationic quaternary ammonium compound, which is a bis-quaternary compound. A composition for extracting hydrocarbons, which contains water and at least one polycationic quaternary ammonium compound, which is a bis-quaternary compound. A polycationic quaternary ammonium compound with a static or ordered structure having the given structural formula. ^ EFFECT: provision for viscoelastic properties at high temperatures, environmental friendliness. ^ 29 cl, 2 tbl, 5 ex, 15 dwg
The invention discloses pure traditional Chinese medicine for treating asthma, and belongs to the technical field of traditional Chinese medicine. The pure traditional Chinese medicine for treating asthma does not contain western medicine ingredients. In clinics, the bronchial asthma mainly includes two main classes of allergia bronchial asthma and non-allergia bronchial asthma. The two kinds of bronchial asthma can simultaneously occur, so that the disease is called as the asthma. The asthma is mainly caused by the following that exterior wind-cold is caught, but the exterior syndrome cannot be relieved in time; pathogenic factors exist in the lung; the fluid cannot be distributed by qi; the fluid is gathered to form phlegm; the diet is improper; a patient eats much raw or cold food; the cold beverage stagnates at the interior; or the patient likes to eat sour, sweet and fat food, and the pathogenic factors seep into the trachea; or seafood, fish or mutton are eaten, so that the spleen-stomach disharmony occurs; the diet is not proper, so that phlegm senescence is generated at the interior; the lung is invaded at the upper side; the yang and the lung qi are obstructed. A patient has a poor constitution, feels weak after the disease, and has pertussis or catches a cold repeatedly; after the cough for a long time, the yang and yin deficiency is caused; the fluid transforming by qi cannot be realized; the phlegm and retained fluid are generated at the interior; or the yin deficiency and yang preponderance occur; the heat is evaporated and the fluid is gathered; the phlegm-heat is solidified; the asthma has the main factor of phlegm, so that the asthma treatment mainly focuses on the phlegm relieving. The phlegm is caused by the following reasons that on the basis of internal organ yin-yang disharmony, the disharmony occurs after the disease; the external infection and diet reasons and the like also exist. The types of medicine for treating the asthma are various in the prior art. The invention provides a treatment method of a pure traditional Chinese medicine preparation prepared by using pure natural plants, animals and minerals as raw materials.
The invention belongs to the technical field of beauty products, and discloses a gene-contained whitening facial mask liquid for solving the problems that the existing mask liquid has a side effect, is poor in whitening and anti-aging effects as well as high in production cost. The gene-contained whitening facial mask liquid comprises a first bottle and a second bottle. The first bottle contains 20 portions of a mixed solution; the second bottle contains 2-5 portions of a mixed solution. The ingredients and the weight percentages of the mixed solution inside the first bottle are as follows: 0.01-7.4% of vitamin C; 0.03-5.6% of vitamin E; 0.8-10.8% of a substrate collagen; 0.4-7.4% of sodium carbonate; the rest is water. The ingredients and the weight percentages of the mixed solution inside the second bottle are as follows: 80-120 milligrams of sir2 gene in each bottle, 90-130 milligrams of SCH9 gene in each bottle, the rest is a preservation solution. The gene-contained whitening facial mask liquid is characterized in that the gene-contained whitening facial mask liquid has no side effects in the using process, has a good whitening effect and a good effect for preventing the aging of the skin.
INTRODUCTION: Reflux bile acids are believed to promote esophageal adenocarcinoma (EAC), but the role of systemic bile acids is unknown. This study aimed to assess associations between systemic bile acids and stages of Barrett's esophagus (BE) progression.
METHODS: Subjects with and without BE were enrolled in this multicenter cross-sectional study. Targeted serum bile acid profiling was performed, and a subset of subjects completed a validated food frequency questionnaire. RNA sequencing was performed on BE or gastric cardia tissue to assess bile acid associations with gene expression.
RESULTS: A total of 141 subjects were enrolled with serum bile acids profiled (49 non-BE; 92 BE: 44 no dysplasia, 25 indefinite/low grade dysplasia, 23 high-grade dysplasia/EAC). Lower Healthy Eating Index score, older age, higher body mass index, and no proton pump inhibitor use were associated with increased levels of multiple bile acids. Global bile acid pools were distinct between non-BE and stages of BE neoplasia ( P = 0.004). Increasing cholic acid was associated with high-grade dysplasia/EAC compared with non-BE, even after adjusting for EAC risk factors (adjusted odds ratio 2.03, 95% confidence interval 1.11-3.71) as was the combination of unconjugated primary bile acids (adjusted odds ratio 1.81, 95% confidence interval 1.04-3.13). High cholic acid levels were associated with tissue gene expression changes including increased DNA replication and reduced lymphocyte differentiation genes.
DISCUSSION: Alterations in serum bile acids are independently associated with advanced neoplasia in BE and may contribute to neoplastic progression. Future studies should explore associated gut microbiome changes, proneoplastic effects of bile acids, and whether these bile acids, particularly cholic acid, represent potential biomarkers or viable therapeutic targets for advanced neoplasia in BE.
The invention discloses a Qiaonan mycin serving as a fungus metabolism product and a preparation method and an application thereof, relating to a separating and purifying method of a novel structural compound of an antitumor necrosis factor and an application thereof. The Qiaonan mycin serving as the fungus metabolism product is shown as C22H18N4O4, which has the molecular weight 402, belongs to a derivative of quinolineformylamine, is white powder, has the specific rotatory power [alpha]D of -27.9(C=0.43, in MeOH), is easily dissolved into methanol, and is hardly dissolved into low-polarity solvents such as chloroform and the like. The structure of the compound is not reported till now. On a cell model for screening a TNF-alpha antagonist, the compound shows high antagonistic activity. The Qiaonan mycin serving as the fungus metabolism product can be used for preparing an anti-inflammatory medicament or other bioactive primers. The Qiaonan mycin serving as the fungus metabolism product can be used for preparing an anti-inflammatory medicament or other bioactive primers by fermenting, generating, separating and purifying.
Introduction: Transurethral injections into the bladder wall with botulinum toxin are an established treatment for refractory overactive bladder or detrusor overactivity. With the current injection technique, an average of approx. 18% and up to 40% of botulinum toxin is injected next to the bladder wall, potentially causing reduced efficacy or non-response. The article aims to evaluate the reasons for incorrect injections and propose strategies for complete delivery of the entire botulinum toxin fluid into the bladder wall. Material and Methods: Unstructured literature search and narrative review of the literature. Results: Incorrect injection of botulinum toxin fluid next to the bladder wall is caused by pushing the injection needle too deep and through the bladder wall. Bladder wall thickness decreases with increasing bladder filling and has a thickness of less than 2 mm beyond 100 mL in healthy individuals. Ultrasound imaging of the bladder wall before botulinum toxin injection can verify bladder wall thickness in individual patients. Patient movements during the injection therapy increase the chance of incorrect placement of the needle tip. Conclusions: Based on the literature search, it is helpful and recommended to (1) perform pretreatment ultrasound imaging of the bladder to estimate bladder wall thickness and to adjust the injection depth accordingly, (2) fill the bladder as low as possible, ideally below 100 mL, (3) use short needles, ideally 2 mm, and (4) provide sufficient anesthesia and pain management to avoid patient movements during the injection therapy.
The recommended dosage of Ferrlecit for the repletion treatment of iron deficiency in hemodialysis patients is 10 mL of Ferrlecit (125 mg of elemental iron). Ferrlecit may be diluted in 100 mL of 0.9% sodium chloride administered by intravenous infusion over 1 hour per dialysis session. Ferrlecit may also be administered undiluted as a slow intravenous injection (at a rate of up to 12.5 mg/min) per dialysis session. For repletion treatment most patients may require a cumulative dose of 1000 mg of elemental iron administered over 8 dialysis sessions. Ferrlecit has been administered at sequential dialysis sessions by infusion or by slow intravenous injection during the dialysis session itself.

Data from Ferrlecit postmarketing spontaneous reports indicate that individual doses exceeding 125 mg may be associated with a higher incidence and/or severity of adverse events  [see Adverse Reactions (6.2)].
Fibrillated articular cartilage are commonly detected during arthroscopy when treating knee pathologies such as a torn meniscus or a damaged anterior cruciate ligament (ACL). The severity of these lesions is graded using a scheme such as the International Cartilage Research Society (ICRS) classification system. Grade I lesions are often left untreated, while Grade IV lesions require dedicated surgical intervention. Grade II and III lesions are frequently treated when they are encountered arthroscopically.

Currently, it is not known whether treatment of fibrillated articular cartilage is beneficial or whether one procedure is superior to another. Magnetic resonance imaging is the best technique currently available for non-invasive assessment of chondral lesions. The primary aim of the proposed study is to compare post-procedure MR imaging characteristics of fibrillated articular cartilage treated using one of the three standard of care measures: 1) Washing of the knee joint with saline solution to clear blood, fluid or loose tissue (also known as lavage); 2) Lavage in addition to mechanical shaver (a manual surgical tool used by the study doctor); and 3)Lavage in addition to the Paragon device (RF-based microdebridement), which may also be used with a mechanical (or manual) surgical tool. The secondary aim is to determine the association between imaging features and clinical outcomes.
Participants will first receive high-flux hemodialysis. Following a washout period of 1-3 weeks, they will receive post-dilution hemodiafiltration.
Recurrent abdominal pain (RAP) is a functional disorder that affects approximately 10 to 25% of children in the United States. This population tends to be heavy medical users in a search of a treatment for the chronic pain, but at this time there is no standard treatment protocol. The literature proposes that there are two effective treatments for RAP, a relaxation protocol by Sanders et al. (1994) and a biofeedback protocol currently in use at Kaiser, but neither treatment has been widely accepted as standard treatment. A purpose of this study is to gather more data on both treatments to help move one or both treatments into the standard of care for RAP. The hypothesis of this study is that the biofeedback and the relaxation protocols will have equivalent treatment outcomes.